Devyser Diagnostics AB
STO:DVYSR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Devyser Diagnostics AB
Accounts Receivables
Devyser Diagnostics AB
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Devyser Diagnostics AB
STO:DVYSR
|
Accounts Receivables
kr67m
|
CAGR 3-Years
35%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Accounts Receivables
kr222.3m
|
CAGR 3-Years
41%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Accounts Receivables
kr665m
|
CAGR 3-Years
10%
|
CAGR 5-Years
23%
|
CAGR 10-Years
19%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Accounts Receivables
kr7.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
32%
|
|
|
BioArctic AB
STO:BIOA B
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Devyser Diagnostics AB
Glance View
Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.
See Also
What is Devyser Diagnostics AB's Accounts Receivables?
Accounts Receivables
67m
SEK
Based on the financial report for Dec 31, 2025, Devyser Diagnostics AB's Accounts Receivables amounts to 67m SEK.
What is Devyser Diagnostics AB's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
32%
Over the last year, the Accounts Receivables growth was 32%. The average annual Accounts Receivables growth rates for Devyser Diagnostics AB have been 35% over the past three years , 32% over the past five years .
